Research Article
Plasma Small Extracellular Vesicle-Carried miRNA-501-5p Promotes Vascular Smooth Muscle Cell Phenotypic Modulation-Mediated In-Stent Restenosis
Figure 6
Smad3 is target gene of plasma sEV-carried miRNA-501-5p in smooth muscle cells. (a) Screening scheme for putative target gene of miRNA-501-5p. (b) Schematic of miRNA-501-5p putative target sites in the 3URT of Smad3 and the sequences of mutant UTRs. (c) Dual luciferase reporter assay of 293T cells cotransfected with miRNA-501-5p mimic or negative control (NC) (). (d) Representative blots and quantified data showing protein expressions of Smad2, Smad3, and Smad4 in human aortic smooth muscle cells (HASMC) transfected with miRNA-501-5p mimic or NC (). (e) qRT-PCR analysis of Smad2, Smad3, and Smad4 in carotid artery from rats with carotid artery balloon injury (CABI) undergoing sEV injection (). Data are normalized to U6. (f) qRT-PCR analysis of Smad2, Smad3, and Smad4 in carotid artery from rats with carotid artery balloon injury (CABI) undergoing antagomir-501-5p injection (). Data are normalized to U6. Values are . and
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |